Gerald Morris
Internal Medicine · Slidell, LANPI 1871559864
Payments from drug & device makers
Across 64 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$173
- Exact Sciences$133
- Bayer$125
- Lilly USA, LLC$113
- Axsome Therapeutics, Inc.$96
- Gilead$81
- plus $561 from 14 others
What the payments were for
- Food & beverage$1,282100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 8 | $173 |
| Exact Sciences | 6 | $133 |
| Bayer | 6 | $125 |
| Lilly USA, LLC | 7 | $113 |
| Axsome Therapeutics, Inc. | 4 | $96 |
| Gilead | 3 | $81 |
| Astellas Pharma US Inc | 3 | $77 |
| Dexcom, Inc. | 3 | $76 |
| Merck | 5 | $68 |
| Corcept Therapeutics | 4 | $67 |
| Novo Nordisk | 3 | $49 |
| Amgen | 3 | $41 |
| Phadia US Inc. | 2 | $39 |
| Viiv Healthcare Company | 1 | $32 |
| Baxter Healthcare | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Cranial Technologies, Inc | 1 | $19 |
| Pfizer | 1 | $17 |
| Braeburn Inc. | 1 | $16 |
| Alkermes, Inc. | 1 | $16 |
How this compares
$1,282 in reported general payments places this provider in the 65th percentile of 1,528 internal medicine providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 107 | $113,018 |
| JardianceEmpagliflozin | 52 | $59,221 |
| TrulicityDulaglutide | 39 | $38,462 |
| MounjaroTirzepatide | 28 | $31,303 |
| JanuviaSitagliptin Phosphate | 30 | $27,363 |
| EliquisApixaban | 27 | $16,435 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 68 | $8,165 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $6,066 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $5,206 |
| Novolog FlexpenInsulin Aspart | 22 | $3,254 |
| Gabapentin | 261 | $2,713 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $2,157 |
| Clonidine | 23 | $2,067 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 106 | $1,957 |
| Atorvastatin Calcium | 314 | $1,835 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $49 | $113,018107 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $113 | $69,76567 claims |
| MerckJanuvia | $68 | $27,36330 claims |
| PfizerEliquis | $17 | $16,43527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Slidell
- Allan LarcenaSlidell$152K
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
- Katherine PearceBaton Rouge$12M
- Ernest ThompsonBaker$2.1M
- Brian LewisNew Orleans$2M
- Otis BarnumNatchitoches$1.8M
- Satinder SainiCrowley$1.8M
- Randall MillerEunice$1.2M
- Donna RyanBaton Rouge$991K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.